Holen Sie sich die Stockscreener-App
3.33
0.30%
-0.010
Handel nachbörslich:
3.39
0.06
+1.80%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune director Gill buys $31k in company stock - investing.com
Altimmune (ALT) director makes open-market share purchase - stocktitan.net
Despite Recent Gains, Altimmune Insiders Are Still Down US$29k - Moomoo
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - MSN
Altimmune Inc.’s New Price Target Ignites Investor Interest - timothysykes.com
Altimmune Stock Outlook Brightens as Analysts Raise Price Targets - StocksToTrade
Altimmune’s Stock Target Raised as MASH Program Gains Momentum - timothysykes.com
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street - TipRanks
Altimmune’s Price Surge After H.C. Wainwright Strengthens Outlook - StocksToTrade
ALT stock has nearly halved in the past year, so why does Wall Street see almost 500% upside? - MSN
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune (ALT) CFO adds 10,000 shares in open-market stock purchase - stocktitan.net
Altimmune (NASDAQ: ALT) CEO adds 15,000 shares in open-market buy - stocktitan.net
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmu - GuruFocus
Options Flow: Will Altimmune Inc announce a stock split2026 Market WrapUp & Real-Time Buy Signal Alerts - baoquankhu1.vn
Top 10 stocks under $5 that could triple - MSN
ALT (Altimmune) Common Stock : $0.01 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) Shares Outstanding (Diluted Average) : 105.82 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) 5-Year RORE % : -16.56% (As of Dec. 2025) - GuruFocus
Pullback Watch: Can Altimmune Inc disrupt its industrySell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Altimmune Inc. (ALT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALT (Altimmune) FCF Yield % : -17.19 (As of Mar. 27, 2026) - GuruFocus
ALT (Altimmune) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2025) - GuruFocus
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Jefferies reiterates Buy on Altimmune stock, keeps $28 target - Investing.com UK
Jefferies reiterates Buy on Altimmune stock, keeps $28 target By Investing.com - Investing.com India
Vanguard subsidiaries disaggregate holdings; Altimmune (NASDAQ: ALT) showing 0 shares - Stock Titan
ALT (Altimmune) EPS without NRI : $-1.01 (TTM As of Dec. 2025) - GuruFocus
Altimmune appoints Luis Sanay as vice president of investor relations to strengthen financial communications - Traders Union
ALT Pemvidutide Uncovered: How It Stands Apart in MASH - Bitget
Altimmune Stock: Balanced Perspective With Major Catalysts Expected in 2026 - Bitget
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms - Yahoo Finance Singapore
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts - TradingView
ALT Pemvidutide Explained: What Makes It Different in MASH - Yahoo Finance
Altimmune a new buy at Truist on pemvidutide promise - MSN
HC Wainwright bullish on Altimmune (ALT) amid growing focus on treatments for metabolic and liver diseases - MSN
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Insider Monkey
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - stocktitan.net
Altimmune outlines 1,800-patient phase III MASH trial and signals cash runway into 2028 as pemvidutide advances - MSN
Growth Value: Can Altimmune Inc stock outperform in a bear marketWeekly Market Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Truist initiates Altimmune stock coverage with buy rating on drug potential - Investing.com Australia
Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment - GuruFocus
Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial - MarketBeat
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):